Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/27/2022* -- Results Q3 2022 -- 0.43 --
10/27/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 0.58 0.53 9.49%
08/03/2022 16:30 EST Earnings Call Q2 2022 -- -- --
04/27/2022 -- Results Q1 2022 0.54 0.46 18.75%
04/27/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/23/2022 -- Results Q4 2021 0.04 -0.01 435.4%
02/23/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/27/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since 7.55%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
URL http://www.bmrn.com
Investor Relations URL https://investors.biomarin.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Oct. 27, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
15.88%
-20.92%
7.64%
-4.51%
-0.70%
3.71%
0.75%
7.61%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-9.34%
-35.06%
1.45%
75.16%
20.71%
-12.78%
-31.86%
77.62%
-9.08%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-13.15%
-2.95%
-60.23%
239.3%
-42.61%
57.96%
12.85%
30.48%
37.90%
0.31%
-22.77%
5.16%
7.48%
11.75%
-6.41%
-46.18%
44.92%
As of August 12, 2022.

Profile

Edit
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
URL http://www.bmrn.com
Investor Relations URL https://investors.biomarin.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Oct. 27, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
URLGX 53.39M USD 4.37%
BBH 16.83M USD 3.47%
FBT 49.43M USD 3.47%
VHCOX 428.69M USD 2.57%
POAGX 164.59M USD 2.30%
POGRX 142.68M USD 2.01%
IBB 135.24M USD 1.61%
JFNSX 54.49M USD 1.32%
QQQJ 11.87M USD 1.32%
CSMZX 44.76M USD 1.15%
XT 23.40M USD 0.72%
SCHM 44.30M USD 0.46%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter BMRN Tweets